COMMENTARY: Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes

Vella, Adrian
January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3
Academic Journal
The author comments on the efficacy of incretin therapy for glycemic control in non-insulin-dependent diabetics. He pointed out that the glucagon-like peptide 1 (GLP1) is associated with a significant incidence of gastrointestinal adverse effects and dipeptidyl peptidase 4 (DDP4) inhibitors are weight-neutral. He suggests that the clinicians and patients must consider the price of the medications for their glucose-lowering efficacy is similar to those established therapies for type 2 diabetes.


Related Articles

  • Review: Incretin therapy improves glycemic control more than placebo in patients with type 2 diabetes.  // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p3 

    The article presents a clinical study that evaluates the efficacy of incretin for glycemic control in adults with non-insulin-dependent diabetes. A randomized-controlled trial showed changes in patients' glycated hemoglobin levels, weight and hypoglycemia. It is concluded that the incretin...

  • Chronic Administration of Alogliptin (SYR-322), a Novel Dipeptidyl Peptidase-IV Inhibitor, Improved Beta-Cell Function in ob/ob Mice. Moritoh, Yusuke; Takeuchi, Koji; Kataoka, Osamu; Asakawa, Tomoko; Odaka, Hiroyuki // Diabetes;Jun2007 Supplement 1, Vol. 56, pA136 

    Alogliptin (SYR-322) is a novel, oral, potent, and highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under development as a once-daily treatment for type 2 diabetes (T2D). The efficacy of alogliptin was investigated in ob/ob mice, an obese model of T2D. Chronic administration of...

  • Gliptins: A New Class of Oral Antidiabetic Agents. SESHADRI, K. G.; KIRUBHA, M. H. B. // Indian Journal of Pharmaceutical Sciences;2009, Vol. 71 Issue 6, p608 

    India has the largest population of patients with type 2 diabetes mellitus. The conventional agents used to treat type 2 diabetes frequently exhibit reduced efficacy over time leading to inadequate glycaemic control and are also associated with adverse effects. Hence, there is a need for...

  • Nonlinear Increase in GLP-1 Levels in Response to DPP-IV Inhibition in Healthy Adult Subjects. Dai, Haiqinq; Gustavson, Stephanie M.; Calle, Roberto A.; Hirshberg, Boaz // Diabetes;Jun2007 Supplement 1, Vol. 56, pA135 

    Dipeptidyl Peptidase IV (DPP-IV) inhibitors represent a new promising target for the treatment of T2DM. The aim of this study was to investigate the effects of DPP-IV inhibition by PF-00734200, a potent competitive DPP-IV inhibitor, on the dynamics of plasma in healthy adult subjects. In a...

  • Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes. Vaidya, H. B.; Goyal, R. K. // Current Drug Targets;Oct2008, Vol. 9 Issue 10, p911 

    Diabetes mellitus (DM) has been recognized as a growing world-wide epidemic by many health advocacy groups including the World Health Organization (WHO). DM affects about 6% of the North American population. A recent report estimated that 8.2% of adult population worldwide has impaired glucose...

  • Long-Acting Glucagon-Like Peptide 1 Receptor Agonists. GARBER, ALAN J. // Diabetes Care;May2011 Supplement 2, Vol. 34, pS279 

    The article examines the efficacy and tolerability of long-acting glucagon-like peptide 1 receptor agonists. The two classes of drugs for treating type 2 diabetes are glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors. A definition of incretin effect is...

  • GLP-1 receptor agonist-induced polyarthritis: a case report. Ambrosio, Maria; Monami, Matteo; Sati, Lavinia; Marchionni, Niccolò; Bari, Mauro; Mannucci, Edoardo // Acta Diabetologica;Aug2014, Vol. 51 Issue 4, p673 

    Occasional cases of bilateral, symmetrical, seronegative polyarthritis have been reported in patients treated with dipeptidyl peptidase-4 inhibitors (Crickx et al. in Rheumatol Int, ). We report here a similar case observed during treatment with a GLP-1 receptor agonist. A 42-year-old man with...

  • Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Russell, Sheldon // International Journal of Clinical Pharmacy;Apr2013, Vol. 35 Issue 2, p159 

    Background Clinical trials comparing incretin-based therapies-glucagon-like peptide-1 receptor agonists (exenatide-twice daily and once weekly-and once-daily liraglutide) and dipeptidyl peptidase-4 inhibitors (vildagliptin, sitagliptin, saxagliptin and linagliptin)-with placebo and oral...

  • Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science. Singh, Awadhesh Kumar // Indian Journal of Endocrinology & Metabolism;Jan/Feb2015, Vol. 19 Issue 1, p182 

    Although GLP-1 (glucagon like peptide-1) based therapies (GLP-1 agonists and dipeptidyl peptidase-4 inhibitors) is currently playing a cornerstone role in the treatment of type 2 diabetes, dilemma does exist about some of its basic physiology. So far, we know that GLP-1 is secreted by the direct...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics